Researchers have discovered that ponatinib, a tyrosine kinase inhibitor approved for chronic myeloid leukemia, works in an entirely unexpected way to enhance cancer-fighting immune cells called CD8+ T stem cell memory (TSCM) cells. In laboratory and animal studies, the drug inhibits two key signaling pathways, LCK and PI3K, which allows immune cells to maintain their stem-like properties and attack tumors more effectively. The finding opens a new therapeutic avenue for improving cancer immunotherapy, particularly when combined with existing checkpoint inhibitor treatments .

What Are T Stem Cell Memory Cells and Why Do They Matter?

T stem cell memory cells are a special subset of immune cells that combine the best features of both fresh immune cells and experienced ones. They can persist in the body for extended periods, multiply rapidly when needed, and generate diverse immune responses against cancer. Unlike exhausted immune cells that lose their fighting ability over time, TSCM cells maintain their vigor and ability to recognize and destroy cancer cells. The challenge has been generating enough of these cells in clinical settings to make immunotherapy more effective .

This is where ponatinib's unexpected benefit comes in. The drug was originally designed to target BCR-ABL1, a protein mutation in leukemia cells. But researchers discovered it also inhibits LCK and PI3K signaling in immune cells, which triggers the activation of two transcription factors, TCF7 and FOXO1. These factors essentially reprogram T cells to become TSCM cells with enhanced tumor-fighting capabilities .

How Does Ponatinib Enhance CAR T Cell Therapy?

Chimeric antigen receptor (CAR) T cell therapy is a cutting-edge cancer treatment where doctors genetically engineer a patient's own immune cells to recognize and attack cancer. However, CAR T cells can become exhausted after prolonged exposure to tumors, losing their ability to fight back. In mouse tumor models, ponatinib treatment increased the number of CAR TSCM cells by reducing this exhaustion, resulting in more durable antitumor effects .

The research also showed that ponatinib works best when its inhibition of LCK and PI3K is stable and sustained over time. Intermittent dosing did not produce the same beneficial effects, suggesting that consistent drug exposure is critical for reprogramming immune cells into the desired TSCM phenotype .

Steps to Understanding Ponatinib's Dual Role in Cancer Treatment

• Primary Mechanism: Ponatinib was originally approved by the FDA in 2012 to treat chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia by targeting the BCR-ABL1 protein mutation.
• Off-Target Immunomodulation: The drug's secondary effects on LCK and PI3K signaling in immune cells activate transcription factors TCF7 and FOXO1, which promote the differentiation of CD8+ T cells into stem cell memory cells with superior tumor-fighting properties.
• Combination Potential: In preclinical studies, ponatinib demonstrated antitumor efficacy both as a standalone treatment and when combined with PD-1 checkpoint blockade inhibitors, a class of drugs that remove the brakes on immune responses.
• CAR T Enhancement: Ponatinib increases the proportion of CAR TSCM cells in engineered immune cell products, reducing CAR T cell exhaustion and enabling more durable responses against tumors in mouse models.

What Do the Study Results Actually Show?

The research, published in Nature Communications, used both mouse tumor models and laboratory studies to evaluate ponatinib's immunomodulatory effects. Researchers conducted RNA-sequencing and single-cell RNA-sequencing analyses to understand how the drug reprograms T cell gene expression. The data revealed that stable inhibition of LCK and PI3K pathways is essential for TSCM cell induction, while intermittent inhibition failed to produce the same results .

In tumor-bearing mice, ponatinib treatment alone showed antitumor efficacy. When combined with PD-1 blockade, a checkpoint inhibitor that enhances immune responses, the combination produced stronger effects. Most notably, ponatinib increased the frequency of CAR TSCM cells in engineered CAR T cell products, which translated to more durable antitumor activity compared to standard CAR T cells .

"Our results implicate ponatinib as a therapeutic immunomodulator, inducing TSCM cells for improved antitumor T cell activity,"

Researchers, Nature Communications Study

Why This Matters for Cancer Patients

The discovery that an existing, FDA-approved drug can enhance immune cell therapy without being specifically designed for that purpose is significant. It suggests that researchers may be able to improve CAR T cell manufacturing and other immunotherapies by incorporating ponatinib into the cell preparation process. This could lead to more effective treatments for patients with certain cancers, particularly those resistant to standard checkpoint inhibitor therapy .

The finding also highlights the importance of studying off-target effects of existing drugs. Ponatinib was developed to fight leukemia, but its secondary effects on immune cell signaling pathways open entirely new therapeutic possibilities. This approach of repurposing approved medications for unexpected benefits could accelerate the development of improved cancer treatments without the lengthy approval timelines required for entirely new drugs .

While these results are promising, the research remains in preclinical stages using mouse models and laboratory studies. Clinical trials in human patients would be necessary to confirm whether ponatinib can safely and effectively enhance CAR T cell therapy or other immunotherapies in real-world settings. Researchers emphasize that the sustained, continuous inhibition of LCK and PI3K signaling is critical, which will require careful dosing strategies in any future human studies.

" }